CytRx News

The research was published in the May 22, 2012 online issue of peer-reviewed Clinical Cancer Research .

CytRx Corporation , a biopharmaceutical company specializing in oncology, today announced a reverse split of its common stock at a ratio of 1-for-7. CytRx's common stock will begin trading on NASDAQ on a split-adjusted basis when the market opens on May 16, 2012.

"We are delighted with recent developments that have strengthened and advanced our program with INNO-206, a proprietary doxorubicin tumor-targeting conjugate," said President and Chief Executive Officer Steven A. Kriegsman.

Management to host investor conference call featuring Dr. Chawla on Monday, June 4, at 10:00 a.m. Eastern time LOS ANGELES-- --May 7, 2012 - CytRx Corporation , a biopharmaceutical company specializing in oncology, today announced that complete data from the Company's Phase 1b/2 clinical trial with its proprietary doxorubicin tumor-targeting ... (more)

CytRx Corporation , a biopharmaceutical company specializing in oncology , today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas who have progressed after receiving two prior therapies.